Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)

Noopur Raje • 5 Oct 2018
ESH MM 2018
Multiple Myeloma Dabrafenib Trametinib Vemurafenib Venetoclax

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses precision medicine in the field of multiple myeloma (MM). Dr Raje covers the example of vemurafenib monotherapy for BRAF mutation postive MM patients, and discusses future plans to combine the BRAF inhibitor dabrafenib with the MEK inhibitor trametinib. She also highlights the fluidity of the term precision medicine and what should be included within this definition. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Noopur Raje

2:06
Challenges with selecting therapy after failure of frontline treatments in R/R multiple myeloma
Noopur Raje • 29 Sep 2023
2:35
Recommendations for managing infections in patients with myeloma treated with bispecifics
Noopur Raje • 29 Sep 2023
1:13
The role of checkpoint inhibitors in multiple myeloma & future considerations for these agents
Noopur Raje • 29 Sep 2023
2:17
Session highlights: practical aspects of immunotherapy in multiple myeloma
Noopur Raje • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals